Telmisartan

Molecular formula C33H30N4O2 Molecular weight 514.62 CAS Registry No 144701-48-4 Merck Index 13,9209 

Sample preparation Inject a 100 jaL aliquot of plasma onto column A and elute to waste with mobile phase A after 3 min, backflush the contents of column A onto column B using mobile phase B after 3 min, elute column B with mobile phase B, monitor the effluent from column B. 

Column A 17 x 4.6 unspecified enrichment column B 125 x 4.6 NucleosU 100-5 CIS Mobile phase A 50 mM pH 4.5 ammonium acetate B MeCN 50 mM pH 4.5 ammonimn acetate 10 90 C Gradient. MeCN 50 mM pH 4.5 ammonium acetate 30 70 for 3 min, to 60 40 over 12 min Flow rate 1 Injection volume 100 Detector F ex 305 em 365 

Heinzel, G. Prox, A. Beschke, K. Wachsmuth, H. Disposition and chemical stability of telmisartan 1-O-acylglucuronide, Drug Metab.Dispos., 1999, 27, 1143-1149. 

Sample preparation Condition a 1 mL 100 mg Bond Elut C8 SPE cartridge with 2 mL MeOH and 1 mL 100 mM pH 6 phosphate buffer. Shake 1 mL urine with 500 [tL 100 mM pH 6 phosphate buffer, centrifuge at 3500 rpm (16.1 g) at 4° for 5 min, add a 1 mL aliquot to the SPE cartridge, wash with 1 mL MeOH 100 mM pH 6 phosphate buffer 30 70, dry under full vacuum for 20 min, elute with 1 mL MeOH. Evaporate the eluate to dryness under a stream of nitrogen at 40°, reconstitute the residue with 500 iL mobile phase, inject a 20 p,L aliquot. 

---

C4H7CIO 141-75-3) see Bunazosin ButofiIolol Etacrynic acid Telmisartan... 

C15HH1N2 120511-72-0) see Anastrozole A -methyl-o-phenylenediamine (C7HK1N2 4760-34-3) see Telmisartan... 

PROFESS is an ongoing large randomized trial examining combination ER-DP plus aspirin therapy compared with clopidogrel (each group also with or without telmisartan, an angiotensin receptor antagonist) for the secondary prevention of early and late recurrent stroke, and other vascular events. 

Pharmacology Losartan, candesartan, irbesartan, olmesartan, telmisartan, eprosartan, and valsartan are angiotensin II receptor (type AT- ) antagonists. 

There was no significant difference in the incidence of cough between losartan, olmesartan, eprosartan, or telmisartan and placebo. Irbesartan use was not... 

Telmisartan- As the majority of telmisartan is eliminated by biliary excretion, patients with biliary obstructive disorders or hepatic insufficiency can be expected to have reduced clearance. Use telmisartan with caution in these patients. 

Creatinine/Blood urea nitrogen (BUN) - Minor increases in BUN or serum creatinine were observed with candesartan, losartan, valsartan, irbesartan, and eprosartan. A rise of 0.5 mg/dL or more in creatinine was observed in 0.4% telmisartan patients compared with 0.3% placebo patients. 

Drugs that may interact with telmisartan include digoxin and warfarin. 

USAN Telmisartan Trade name Micardis Boehringer Ingelheim Launched 1999 M.W. 514.63... 

---